Search PubMed⌕ Search

Biomedical subjects

G Deppe

Publications and source records attributed to G Deppe.

At least 73 records · Page 4Linked to original sources
PubMed1988

Debulking surgery for ovarian cancer with the Cavitron Ultrasonic Surgical Aspirator (CUSA)--a preliminary report.

The Cavitron Ultrasonic Surgical Aspirator (CUSA) can be used to fragment and aspirate tissue precisely. The CUSA was utilized as an adjunctive procedure to standard operative techniques to optimally debulk 11 women with advanced epithelial carcinoma of the ovary. No significant intraoperative or postoperative complications were encountered. It is suggested that this technique may be safely attempted in combination with the standard surgical techniques for debulking nonfibrous ovarian tumors or may allow removal of nonfibrous tumor masses which cannot be resected safely utilizing the standard surgical techniques. The authors found the CUSA's efficiency was limited in dense and fibrotic tissue. On the basis of our experience with this small number of patients, we believe this technique deserves further study.

Antineoplastic Agents↗
PubMed1987

Mycotic aneurysms in pregnancy.

The presentation, management, and outcome of three cases of femoral artery mycotic aneurysm in pregnancy are described. All resulted from illicit intravenous drug use. While the literature dealing with drug abuse in pregnancy is large, this specific problem has received little attention. Comparison of these cases to a large reported series of nonpregnant patients with mycotic aneurysms from our institution demonstrates that pregnancy does not alter the natural course of this condition. The presence of a mycotic aneurysm in pregnancy does, however, appear to lead to significant maternal and fetal morbidity.

Adult↗
PubMed1987

The use of a human endometrial carcinoma cell line (RL-95) for in vitro testing of chemotherapeutic agents.

RL-95, a moderately well-differentiated adenosquamous endometrial carcinoma cell line, can be used as a model for testing chemotherapeutic agents in vitro. Cells are grown in T-75 flasks, transferred to scintillation vials, and grown for 24 hr. Following this, medium is removed and new medium containing Adriamycin (Adr) and cis-platinum (CP) is added. Effects of the two drugs are measured by cell counts and DNA synthesis. To measure DNA synthesis, cells are incubated with [3H]thymidine (3H-THY) for up to 24 hr. Decreased DNA synthesis is reflected in decreased 3H-THY uptake. Cell kill is obtained with levels of drugs that are clinically achievable. Evidence is presented for increased cytotoxicity with concomitant, rather than sequential, chemotherapy. Results are also confirmed by testing the agent on MCF-7, a well-known breast cancer cell line. The results indicate that (1) endometrial carcinoma responds to Adriamycin and cis-platinum chemotherapeutic agents in vitro, and (2) RL-95 can be used as a model for testing varying concentrations, time of exposure, and combinations of chemotherapeutic agents.

Adenocarcinoma↗
PubMed1987

Trichloroacetic acid in the treatment of human papillomavirus infection of the cervix without associated dysplasia.

Human papillomavirus-induced cytologic changes were found in 379 (10.9%) of 3461 Papanicolaou smears done at the Gynecology Clinic at Wayne State University. Of these 379 patients, 98 (25.8%) had no cytologic evidence of dysplasia. Forty-six of the 98 patients, who had colposcopic and histologic evidence of human papillomavirus without dysplasia, agreed to participate in this study. All patients underwent a Q-Tip application of 85% trichloroacetic acid to the entire cervix, including the endocervical canal and the transformation zone, until the mucosa turned white. Coexistent vaginal and vulvar condyloma were treated simultaneously in six patients. The patients were reexamined at two-week intervals to ascertain the need for reapplication of trichloroacetic acid. No colposcopic evidence of human papillomavirus was found in 18 patients at the first visit, whereas 28 patients required reapplication of trichloroacetic acid. Three months after treatment, a follow-up Papanicolaou smear and colposcopic examination revealed no human papillomavirus infection in 31 patients. Seven patients had persistent infection and eight patients were lost to follow-up. Our preliminary data from this study suggest that 85% trichloroacetic acid is effective treatment of human papillomavirus infection of the cervix without dysplasia.

Colposcopy↗
PubMed1987

Vaginal müllerian stromal sarcoma. A case report.

Primary malignancies of the vagina are among those encountered most rarely in the female reproductive tract. Even more rare are primary vaginal sarcomas. The fourth case of vaginal müllerian stromal sarcoma is reported on here.

Aged↗
PubMed1986

Surgical approach to diaphragmatic metastases from ovarian cancer.

Fourteen patients underwent surgical debulking of diaphragmatic metastases as part of cytoreductive surgery for advanced ovarian epithelial cancer from 1983 to 1984. The surgical technique is described. Morbidity from this approach was not excessive in this small series of patients. It is suggested that this technique can be safely used and may benefit a few patients with advanced ovarian cancer.

Carcinoma↗
PubMed1986

Pharmacokinetics of mitomycin-C in plasma and tumor tissue of cervical cancer patients and in selected tissues of female rats.

Mitomycin-C (MMC) is an alkylating agent which has shown significant activity in gynecologic cancers, both in vivo and in vitro. We determined the delivery of MMC to target tissue by comparing plasma and tumor tissue concentrations of MMC as measured by high-performance liquid chromatography (HPLC) in five patients with cervical cancer. In a companion study, we measured MMC concentrations in plasma and selected tumors of female rats given an equivalent dose. In patients, the mean terminal half-life and total body clearance rates of MMC were 40 min and 275 ml/min/m2, respectively. The mean cervical tumor to plasma concentration of MMC was 1.26 +/- 0.34 (mean +/- SE, n = 4). In female rats, the terminal half-life and total body clearance rates of MMC were 28.4 min and 270 ml/min/m2, respectively. Tissue concentrations of MMC in rats were lower than plasma concentrations measured at corresponding times. The highest concentrations were found in lung and uterus (including cervix) with lower concentrations in ovary and liver. The mean half-life for elimination of MMC from tissues of rats was 20.3 +/- 2.8 min (mean +/- SE, n = 6). Based on similar pharmacokinetic parameters in rats and patients, the rat appears to be a suitable model for the disposition of MMC in human patients. The near equivalent drug concentrations found in tumor and plasma of patients suggests that the in vitro tests conducted at concentrations based on plasma level may be relevant to cervical tumor tissue, as well.

Adenocarcinoma, Mucinous↗
PubMed1986

Ovarian carcinoid and pregnancy. A case report.

The first known case of a primary pure ovarian carcinoid in pregnancy occurred. Urinary 5-hydroxyindol acetic acid (5-HIAA) assays were negative despite elevated whole blood serotonin levels. Careful surgical staging and serial determinations of 5-HIAA and serotonin are recommended for detecting evidence of recurrent or metastatic disease.

Adult↗
PubMed1985

Fractured ureteral catheters in gynecologic oncology.

Two cases of fractured polyethylene double-pigtail ureteral catheters in pelvic cancer patients are reported. Current literature leaves a large void in guiding the management of these catheters. Surveillance techniques to help avoid complications in patients requiring these catheters are suggested.

Carcinoma, Squamous Cell↗
PubMed1985

Phase I trial of carboplatin-cyclophosphamide and iproplatin-cyclophosphamide in advanced ovarian cancer: a Southwest Oncology Group study.

The Southwest Oncology Group has carried out a phase I clinical trial of carboplatin plus cyclophosphamide and iproplatin plus cyclophosphamide in 20 patients with stages III and IV ovarian cancer prior to initiating a phase III trial to compare these platinum analog-cyclophosphamide combinations with standard cisplatin-cyclophosphamide therapy. Myelosuppression proved the dose-limiting toxicity of both the carboplatin (300 mg/m2) plus cyclophosphamide (600 mg/m2) and iproplatin (180 mg/m2) plus cyclophosphamide (600 mg/m2) regimens. Evaluating up to six courses of therapy (repeated at 4-week intervals), the median nadir WBC and platelet counts associated with carboplatin-cyclophosphamide therapy were 1800 (range, 900-4000) and 69 000 per microliter, respectively, and those associated with iproplatin-cyclophosphamide therapy were 1400 (1100-1600) and 140 000 per microliter, respectively. Although the starting doses of carboplatin and iproplatin required a median decrease of 25%, the median doses of each administered through six courses of therapy were 300 and 180 mg/m2, respectively. Neither nephrotoxicity nor neuropathy were experienced by the patients, but mild to moderate nausea and vomiting occurred in more than 75% of those treated with either drug combination. Alopecia of mild to severe degree was observed in 40% of patients. Although the results of this phase I trial are still preliminary, we can recommend for future phase III trials 300 mg/m2 carboplatin and 180 mg/m2 iproplatin when combined with 600 mg/m2 cyclophosphamide repeated a 4-week intervals for six treatment courses.

Adult↗
PubMed1985

Retroperitoneal pelvic lipoma.

A patient with a retroperitoneal pelvic lipoma is presented. Preoperative assessment with computed axial tomography led to the presumptive diagnosis of a fat-containing tumor. Management and differential diagnosis of retroperitoneal tumors are described.

Adult↗
PubMed1984

Nonhormonal chemotherapy in endometrial cancer--a review.

A review of single agents and combination chemotherapy, with or without progestins, in the treatment of recurrent or metastatic endometrial carcinoma is presented. Doxorubicin, hexamethylmelamine, and cis-diamminedichloroplatinum are considered to be the most active drugs for the treatment of this disease. To date, combination chemotherapy has not shown any advantage over single agent therapy. The role of progestins in the treatment depends upon the presence of progesterone receptor binding sites. Better designed, randomized multi-institutional trials, using these drug combinations or new agents, singly or in combination, are necessary to identify optimal chemotherapy for patients with advanced or recurrent endometrial cancer.

Adult↗